[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-post-prostatectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-post-prostatectomy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,59,94,123,146,188,219,244,266,294,319,344,373,397,430,452],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100630129","non-inferiority-study-comparing-salvage-pelvic-radiotherapy-in-25-fractions-625-gy25-versus-20-fractions-525-gy20-for-recurrent-prostate-cancer-after-surgery-100630129",false,"NCT07483658","Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy\u002F25) Versus 20 Fractions (52.5 Gy\u002F20) for Recurrent Prostate Cancer After Surgery.","Non-Inferiority Study Comparing Hypofractionated Post-Operative Salvage Radiotherapy Regimens: 45\u002F62.5 Gy in 25 Fractions vs. 43\u002F52.5 Gy in 20 Fractions for Grade 2+ GU or GI Toxicity (HYP-OP-RT)","HYP-OP-RT","Inclusion Criteria:\n\n* Histologically confirmed prostate adenocarcinoma.\n* Prior radical prostatectomy with detectable PSA (≥0.2 ng\u002FmL).\n* No evidence of distant metastasis (confirmed via bone scan and CT\u002FMRI or TEP-PSMA if PSA is above 0.5 ng \u002Fml).\n* Patient with Nodal recurrence within the pelvis are eligible\n* ECOG performance status 0-2.\n* Age ≥ 18 years.\n* Adequate baseline renal, hepatic, and hematologic function.\n\nExclusion Criteria:\n\n* Prior pelvic radiotherapy.\n* Macroscopic local relapse on imaging\n* Presence of metastatic disease.\n* Active inflammatory bowel disease or other GI conditions predisposing to radiation toxicity.\n* Uncontrolled comorbidities affecting study participation.\n* Prior systemic therapy for recurrent prostate cancer (except ADT within 6 months).","MALE","18 Years",{"count":20,"type":21},434,"ESTIMATED","INTERVENTIONAL",[24],"NA","Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA). The goal is to see if a shorter treatment schedule is as safe and effective as the standard schedule.\n\nWhy is this study important? After prostate surgery, cancer can return in up to 70-80% of high-risk patients. Radiotherapy helps control this, but the best way to deliver it-especially the number of sessions and whether to treat the pelvic area-is still being studied. Shorter treatments could mean less time in therapy and better quality of life, if such treatments are proven safe.\n\nWhat is being compared?\n\nStandard treatment (Arm A):\n\n25 sessions (about 5 weeks) Prostate bed: 62.5 Gy Pelvis: 45 Gy\n\nShorter treatment (Arm B):\n\n20 sessions (about 4 weeks) Prostate bed: 52.5 Gy Pelvis: 43 Gy\n\nBoth groups may also receive hormone therapy (ADT) for 6-24 months.\n\nMain Goal To check if the shorter treatment causes no more side effects (urinary or bowel problems) than the standard treatment, while keeping cancer control similar.\n\nOther Things to be Measured\n\nCancer control (PSA levels, spread of disease) Survival Quality of life (urinary, bowel, sexual health questionnaires)\n\nWho can join?\n\nMen who:\n\nHad prostate surgery Have a detectable PSA (≥0.2 ng\u002FmL) No distant metastasis Are in good general health (ECOG 0-2)\n\nHow long will the study last?\n\nAbout 12 years total:\n\n2 years to enroll patients 10 years of follow-up",[27,28,29,30,31,32],"Reccurent\u002FMetastatic Solid Tumor Disease","Prostate Cancer (Post Prostatectomy)","Prostate Cancer","Prostatic Neoplasms","Neoplasm Recurrence, Local","Biochemical Recurrence of Malignant Neoplasm of Prostate",[34,35,36,37,38,39,40,41,42,43,44,45],"Radiotherapy, Adjuvant","Radiotherapy, Intensity-Modulated","Radiotherapy, High-Dose Hypofractionated","Pelvic Radiotherapy","Androgen Deprivation Therapy","Randomized Controlled Trials","Noninferiority Trials","Quality of Life","Treatment Outcome","Gastrointestinal Diseases \u002F chemically induced","Urinary Tract Diseases \u002F chemically induced","Radiation Injuries","RECRUITING","2026-06-29",{"date":49,"type":50},"2026-07-01","ACTUAL",{"date":52,"type":50},"2026-05-13",{"date":54,"type":21},"2036-02",{"name":56,"class":57},"CHU de Quebec-Universite Laval","OTHER",4,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100629665","phase-3-radiotherapy-after-prostatectomy-for-node-positive-prostate-cancer-100629665","NCT07477626","Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","Radiotherapy and Androgen Deprivation Therapy Versus Androgen Deprivation Therapy Alone After Prostatectomy for Node Positive Prostate Cancer (RADVAN): A Multicenter, Randomized Controlled Phase Ⅲ Trial","RADVAN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed adenocarcinoma of the prostate.\n* Radical prostatectomy with pelvic lymph node dissection and pathologically confirmed positive pelvic lymph nodes (AJCC 8th edition: external iliac, internal iliac, obturator, presacral, periprostatic, and\u002For perirectal nodes).\n* ECOG performance status 0-2.\n* Started postoperative GnRH agonist or antagonist therapy for less than 1 year if receiving postoperative androgen deprivation therapy\\*.\n* Adequate major organ function, defined as:\n\nHemoglobin ≥ 90 g\u002FL Platelet count ≥ 75 × 10⁹\u002FL Total bilirubin ≤ 3 × ULN AST or ALT ≤ 5 × ULN\n\n* Use of effective contraception during the study and for 3 months after.\n* Written informed consent provided, with willingness and ability to comply with study visits, treatments, and procedures.\n\n  * Prior postoperative ARAT use ≤ 3 months is eligible after treatment discontinuation.\n\nExclusion Criteria:\n\n* Measurable pelvic recurrence on postoperative MRI or CT (RECIST 1.1, including prostate bed and lymph nodes).\n* Radiographically confirmed distant metastasis (M1a, M1b, or M1c).\n* Neoadjuvant hormonal therapy \\> 3 months before prostatectomy.\n* Malignancy within 5 years that may interfere with study safety or efficacy assessments.\n* Castration-resistant prostate cancer (CRPC) prior to enrollment per 2025 EAU criteria\n* Prior radiotherapy overlapping irradiation fields that may compromise normal tissue.\n* Serious comorbidities affecting study treatment.\n* Psychiatric disorders preventing understanding or compliance.\n* Any condition that, in the investigator's judgment, makes participation unsuitable.",{"count":68,"type":21},372,[70],"PHASE3","The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically confirmed regional lymph node-positive (pN1) prostate cancer after radical prostatectomy.\n\nThe main questions it aims to answer are:\n\n* Does ADT combined with pelvic radiotherapy improve biochemical recurrence-free survival (bRFS) compared with ADT alone in pN1 patients?\n* Does the addition of pelvic radiotherapy improve clinical progression-free survival, metastasis-free survival, overall survival, and prostate cancer-specific survival without unacceptable toxicity?\n\nResearchers will compare ADT plus pelvic radiotherapy with ADT alone to see if combined treatment improves disease control and long-term clinical outcomes.\n\nParticipants with positive lymph nodes after prostatectomy will be randomly assigned in a 2:1 ratio to receive ADT plus pelvic radiotherapy, or ADT alone. ADT will be administered for 2 years. Patients with radiologically detectable pelvic recurrence or distant metastases after radical prostatectomy will be excluded. Safety, adverse events, and health-related quality of life will be assessed during follow-up.",[28,73,74,38,75],"Radiotherapy; Image-Guided","Prostate Cancer Non-Metastatic","Lymph Node Positive",[77,78,79,80,81,82,83],"prostate cancer","node positive","pN1","radiotherapy","androgen deprivation therapy","hormone therapy","prostatectomy","2026-06-15",{"date":86,"type":50},"2026-06-16",{"date":88,"type":50},"2026-03-20",{"date":90,"type":21},"2038-12-31",{"name":92,"class":57},"Sun Yat-sen University",13,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100640577","effects-of-rectal-indomethacin-suppository-on-postoperative-crbd-in-patients-undergoing-lrp-100640577","NCT07607990","Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP","Effects of Rectal Indomethacin Suppository on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Laparoscopic Radical Prostatectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 80 years old (inclusive);\n2. American Society of Anesthesiologists (ASA) physical status classification Class I-III;\n3. Undergoing elective laparoscopic radical prostatectomy under general anesthesia;\n4. Having a clear understanding of the study, voluntarily participating, and providing informed consent signed by themselves or their family members.\n\nExclusion Criteria:\n\n1. Pre-existing bladder diseases, such as overactive bladder (frequency of micturition \\> 3 times per night or \\> 8 times within 24 hours), neurogenic bladder, and bladder outlet obstruction;\n2. Postoperative status of pelvic organs or spine that affects bladder function;\n3. Postoperative status of total proctocolectomy;\n4. Severe cardiac insufficiency (activity tolerance \\\u003C 4 METs) or clearly diagnosed coronary heart disease;\n5. Clearly diagnosed chronic obstructive pulmonary disease (COPD) or a history of asthma;\n6. Hepatic insufficiency with Child-Pugh Class C;\n7. Chronic kidney disease requiring dialysis;\n8. Active peptic ulcer\u002Fhemorrhagic disease;\n9. Body mass index (BMI) ≤ 18 kg\u002Fm² or ≥ 28 kg\u002Fm²;\n10. Chronic analgesic abuse;\n11. Use of other nonsteroidal anti-inflammatory drugs (NSAIDs) within one week;\n12. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs);\n13. Mental or neurological disorders that prevent the completion of rating scales; or cognitive impairment resulting in the loss of capacity for civil conduct.","80 Years",{"count":103,"type":21},130,[24],"The postoperative incidence of catheter-related bladder discomfort (CRBD) ranges from 47% to 95%. It increases postoperative pain and agitation, thus requiring early intervention. Although a variety of drugs are used for the prevention or treatment of CRBD, the adverse reactions of most of these drugs have limited their clinical application. In long-term clinical practice, we found that indomethacin suppository has a good therapeutic effect on the discomfort of pelvic-related organs caused by nociceptive stimulation. However, its preventive effect on CRBD has not been reported yet. We hypothesized that indomethacin suppository has a preventive effect on postoperative CRBD. To verify this hypothesis, patients undergoing laparoscopic radical prostatectomy were enrolled in the study. Patients in the intervention group received 50 mg of indomethacin suppository via the rectal route immediately after surgery, while those in the control group received no treatment. The severity of CRBD, pain scores, consumption of analgesics, other perioperative adverse reactions, and patient satisfaction were observed and recorded at 0, 1, 2, and 6 hours after surgery.",[28,107,108],"Perioperative Anesthetic","Catheter-related Bladder Discomfort (CRBD)",[110,111,112],"catheter-related bladder discomfort","CRBD","radical prostatectomy","2026-05-25",{"date":115,"type":50},"2026-05-27",{"date":117,"type":50},"2026-01-01",{"date":119,"type":21},"2026-12-31",{"name":121,"class":57},"Zhejiang University",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":144,"locationsCount":122},"100596435","the-effect-of-pelvic-floor-muscle-exercises-after-radical-prostatectomy-100596435","NCT07045415","The Effect of Pelvic Floor Muscle Exercises After Radical Prostatectomy","The Effect of Pelvic Floor Muscle Exercises on Urinary Incontinence Management and Quality of Life in Patients Undergoing Radical Prostatectomy","Inclusion Criteria:\n\n* Being 40 years of age or older Not having urinary incontinence before surgery Having undergone Radical Prostatectomy surgery due to prostate cancer Patients who did not have urinary incontinence before surgery\n\nExclusion Criteria:\n\n* Patients with congenital anomalies of the urinary system, serious organ dysfunctions (liver or kidney failure, advanced heart failure, coagulopathy), neuropsychiatric disorders, presence of active infection, and history of major abdominal or pelvic surgery will not be included in the study.","40 Years","90 Years",{"count":133,"type":21},10,[24],"Cancer, a major public health problem worldwide, was one of the leading causes of mortality in 2020, accounting for approximately 10 million deaths. With 1.41 million new cases reported in the same year, prostate cancer is the fourth most common cancer type globally (Ferlay et al., 2021). Prostate cancer is not only one of the most common types of cancer in men, but it also ranks second among cancer-related deaths in men worldwide (Rahnama'i et al., 2021). Radical prostatectomy (RP) is a treatment method that involves the surgical removal of the prostate gland and surrounding tissues, to stop the progression of the disease and improve the patient's quality of life (Göktas et al., 2015; Litwin and Tan, 2017). Following radical prostatectomy, a curative treatment method commonly used to prevent metastasis, mortality rates remain low; however, the procedure carries a relatively high risk of morbidity (Akarken et al., 2020; Evren and Taşcı, 2021).\n\nThe most common complication encountered by patients after RP is urinary incontinence (Choiniere et al., 2022; Rahnama'i et al., 2021). Urinary incontinence (UI) arises due to factors such as damage to the internal sphincter, external rhabdosphincter, and supportive structures of the urethra during surgery, as well as the involvement of the neurovascular bundle and the development of postoperative fibrosis (Castellan et al., 2023). UI developing after radical prostatectomy significantly reduces patients' quality of life and negatively affects their social adaptation. Therefore, understanding the factors influencing the development of UI after radical prostatectomy is of great importance in determining appropriate treatment approaches and optimizing management (Bernardes et al., 2019; Storås et al., 2020). In the literature, the incidence rates of incontinence after radical prostatectomy range from 0.8% to 87%, and these differences are attributed to various factors such as surgical technique, patient characteristics, and evaluation methods (Boorjian et al., 2012; Hodges et al., 2019; Grise et al., 2017; Pastero et al., 2017).\n\nIn the majority of patients, moderate to severe urinary incontinence is observed in the first few weeks after surgery. In some patients, this condition may persist for months or even years. Urinary incontinence can lead to various psychosocial effects such as shame, loss of self-esteem, impaired mental well-being, anxiety, relationship and sexual dysfunction, and social isolation (Kadono et al., 2016; Zachovajeviene et al., 2017). This condition has a significant impact on patients' physical, social, and emotional well-being, as well as their daily activities, and can contribute to social isolation by causing feelings of embarrassment (Castellan et al., 2023; Ouanes et al., 2022).\n\nNurses play an important role in the management of urinary incontinence that develops after RP. Nurses can educate patients about urinary incontinence, teach conservative treatment methods such as pelvic floor muscle exercises (PFME), and provide psychological support to make the process more manageable (Milios et al., 2019; Tosunöz et al., 2018; Wang et al., 2018). PFME is an effective method that stands out in the rehabilitation of incontinence after RP, and it is one of the most common practices aimed at increasing the strength of the pelvic floor muscles to eliminate sphincter weakness (Castellan et al., 2023; Chitre and Kulkarni, 2023; Pratiwi et al., 2020). Studies on the effectiveness of PFME indicate that these exercises can improve patients' urinary control (Azal et al., 2022). Nurses play a significant role in promoting pelvic floor muscle health by providing information and implementing educational programs and practices to ensure that these exercises are taught and performed correctly (Jalalinia et al., 2020; Storås et al., 2020).\n\nThis study aims to evaluate the effects of preoperative and postoperative nursing interventions on urinary incontinence management and quality of life in patients who have undergone RP. In this context, the effects of nursing interventions (education, pelvic floor muscle exercises, bladder training, etc.) on urinary incontinence severity, quality of life, and patient satisfaction will be examined comparatively. The study aims to identify the most effective nursing interventions in the management of urinary incontinence after RP and to integrate these interventions into clinical practice.",[28,137],"Urinary Incontinence (UI)","NOT_YET_RECRUITING","2026-05-21",{"date":141,"type":50},"2026-05-26",{"date":139,"type":21},{"date":139,"type":21},{"name":145,"class":57},"KTO Karatay University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100630230","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-prostate-cancers-in-algeria-100630230","NCT07484971","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","CLIQQC","Inclusion Criteria:\n\n* Patients aged 19 years and older.\n* Diagnosis of prostate cancer confirmed histologically and\u002For biologically.\n* Patients followed in the participating oncology departments.\n* Written informed consent obtained.\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma\n* Secondary tumors\n* Participation in an interventional study","19 Years",{"count":155,"type":21},2000,"OBSERVATIONAL","The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[29,159,28,160,161,162],"Prostate Cancer (Diagnosis)","Prostate Cancer Patients Treated by Radiotherapy","Prostate Cancer Metastatic","Prostate Cancer (Adenocarcinoma)",[164,165,29,166,167,168,169,170,171,172,173,174,175,176,177],"oncology","patient outcome","Prostate Cancer in Algerian patients","Observational Study","Retrospective data","Treatment strategies","Diagnostic approaches","Clinical characteristics","Epidemiological data","Demographic data","Cross-sectional study","Real-world data","Algeria","Algerian Study","2026-04-14",{"date":180,"type":50},"2026-04-17",{"date":182,"type":50},"2025-07-21",{"date":184,"type":21},"2026-07-21",{"name":186,"class":57},"Société Algérienne de Formation et Recherche en Oncologie",24,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":122},"100632994","the-effect-of-mobile-based-perioperative-education-on-urinary-incontinence-and-erectile-function-after-radical-prostatectomy-100632994","NCT07520916","The Effect of Mobile-Based Perioperative Education on Urinary Incontinence and Erectile Function After Radical Prostatectomy","The Effect of Mobile-Based Perioperative Education on Urinary Incontinence and Erectile Function After Radical Prostatectomy: A Randomized Controlled Trial","MPE-RP","Inclusion Criteria:\n\n* Patients diagnosed with prostate cancer and scheduled for elective radical prostatectomy (open, laparoscopic, or robotic)\n* Aged 18 years or older\n* Planned to undergo surgery at the study center(s)\n* Able to use a smartphone and having sufficient digital literacy to operate the mobile application\n* Provided written informed consent after being informed about the study\n\nExclusion Criteria:\n\n* Pre-existing urinary incontinence or erectile dysfunction before surgery\n* Severe cognitive impairment or severe visual or hearing impairment\n* Previous pelvic radiotherapy or a history of major pelvic surgery\n* Presence of severe comorbidity or terminal illness that may interfere with adherence to the study protocol\n* Technological insufficiency preventing the use of the mobile application",{"count":197,"type":21},78,[24],"This prospective randomized controlled study aims to evaluate the effect of mobile-based perioperative education on postoperative urinary incontinence and erectile function in patients undergoing radical prostatectomy. Patients scheduled for radical prostatectomy will be assigned to either an intervention group or a control group. The intervention group will receive standard care plus a structured mobile application-based perioperative education program including video-assisted pelvic floor muscle training, perioperative education modules, reminders, and follow-up components. The control group will receive routine perioperative care and standard patient education. Data will be collected preoperatively, after urinary catheter removal, and at 1 month and 3 months after surgery. The primary outcomes are urinary incontinence and erectile function, assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), the International Index of Erectile Function-5 (IIEF-5), and a 24-hour pad assessment. Secondary outcomes include lower urinary tract symptoms and disease-specific quality of life assessed by the International Prostate Symptom Score (IPSS), psychological status assessed by the Depression Anxiety Stress Scale-21 (DASS-21), and system usability assessed by the Turkish version of the Computer System Usability Questionnaire-Short Version (T-CSUQ-SV)",[28,137,201],"Erectile Dysfunction Following Radical Prostatectomy",[203,204,205,206,207,208,209],"Radical Prostatectomy","Mobile Health","mHealth","Perioperative Education","Pelvic Floor Muscle Training","Urinary Incontinence","Erectile Function","2026-04-03",{"date":212,"type":50},"2026-04-09",{"date":214,"type":50},"2026-04-02",{"date":216,"type":21},"2027-04-02",{"name":218,"class":57},"Giresun University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":228,"studyType":156,"phases":4,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":122},"100632684","prognostic-value-of-early-postoperative-prostate-specific-antigen-for-oncological-outcomes-after-radical-prostatectomy-100632684","NCT07516886","Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy","PPSARP","Inclusion Criteria:\n\n* Patient is an adult biological male.\n* Patient has morphologically confirmed and untreated prostate cancer.\n* Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy.\n* Patient is informed about this observational study and has signed the informed consent form.\n\nExclusion Criteria:\n\n* Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation.\n* Patient received neoadjuvant prostate cancer treatment.\n* Patient is set to receive adjuvant treatment.\n* Patient has any contraindications for the operation.",{"count":227,"type":21},500,"10 Years","This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.\n\nNo investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.",[28,162,159,231,203],"Prostate Specific Antigen",[77,233,234,112],"persistent prostate-specific antigen","prostate-specific antigen","2026-04-01",{"date":237,"type":50},"2026-04-08",{"date":239,"type":50},"2024-01-22",{"date":241,"type":21},"2039-07",{"name":243,"class":57},"Lithuanian University of Health Sciences",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":251,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":122},"100588435","salvage-ultrahypofractionated-postoperative-external-radiotherapy-for-biochemical-recurrence-100588435","NCT06941363","Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence","SUPERB","Inclusion Criteria:\n\n* Subjects of male sex ≥ 18 years of age.\n* Subjects have freely signed the pertinent informed consent before the beginning of the study\n\n  * Adenocarcinoma of the prostate treated with radical prostatectomy (any type of radical prostatectomy is permitted including retropubic, perineal, laparoscopic or robotically assisted; there is no time limit for the date of radical prostatectomy)\n  * Detectable post-prostatectomy PSA of ≥ 0.1 - \\\u003C 2.0 ng\u002FmL either (1) persistently detectable post-operatively or (2) developing biochemical recurrence after prostatectomy (initially undetectable)\n  * No evidence of N1 and\u002For M1 disease assessed by PSMA PET-CT within 90 days prior to registration\n  * Negative Magnetic Resonance Imaging (MRI) of the pelvis in case of equivocal evidence of local relapse on PSMA PET-CT\n  * Androgen deprivation therapy (ADT) allowed as per physician's discretion\n  * ECOG performance status of 0-1\n  * Ability to complete the questionnaires\n\nExclusion Criteria:\n\n* N1 and or M1 patients\n* Macroscopic local relapse at pelvic MRI.\n* Prior radiation of any kind to the prostate gland or pelvis\n* Prior brachytherapy\n* History of inflammatory colitis or other active severe comorbidities\n* Patients who are on immunosuppressant medication",{"count":252,"type":21},50,"Recently, the Radiation Oncology Department at Fondazione IRCCS San Gerardo dei Tintori has been renovated and has been equipped with cutting edge technologies to treat prostate cancer. Specifically, the now available technology can track organ motion in real time, thus allowing improved precision in radiation delivery, with increased protection of the surrounding organs at risk. These facilities have already enabled the kickoff of two prospective observational trials, the ABRUPT and the POPART, which are currently ongoing in the treatment of intact prostate and the biochemical recurrence, respectively. Taken together, these observations provide the basis for the prospective clinical study herein proposed. Patients enrolled in the study will undergo salvage single stereotactic RT to the prostate bed by means of image guided volumetric intensity-modulated arc technique (IGRT-VMAT) and state-of-the-art treatment-planning and quality assurance procedures, with emphasis on normal tissue sparing and and pinpoint delivery accuracy via the use of devices that ensure stability and beam location reproducibility",[28],[256],"biochemical recurrence; salvage RT; toxicity profile; oncological outcomes; linac-based SBRT","2026-01-29",{"date":259,"type":50},"2026-02-02",{"date":261,"type":50},"2025-05-02",{"date":263,"type":21},"2033-05",{"name":265,"class":57},"University of Milano Bicocca",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":122},"100617913","adaptive-radiotherapy-for-genitourinary-cancers-100617913","NCT07324798","Adaptive Radiotherapy for Genitourinary Cancers","Prospective Study of siMultaneous Adaptive RadioTherapy for Local Boost for Prostate and Bladder Cancers (SMART-B01)","SMART-B01","Inclusion Criteria:\n\n* Patients with newly diagnosed or metastatic\u002Frecurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;\n* Age ≥ 18 years;\n* ECOG performance status score 0-2;\n* No prior radiotherapy history within the current radiation field;\n* No contraindications for MRI scanning;\n* No contraindications for radiotherapy.\n\nExclusion Criteria:\n\n* Patients with contraindications to radiotherapy;\n* Patients unable to tolerate MRI or with contraindications to MRI scanning.",{"count":275,"type":21},60,[24],"The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are:\n\nDoes adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy?\n\nParticipants will:\n\nUndergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion",[28,279],"Bladder Cancer",[77,281,282,283,284],"bladder cancer","adaptive radiotherapy","post-prostatectomy","bladder-conserving treatment","2025-12-29",{"date":287,"type":50},"2026-01-07",{"date":289,"type":50},"2024-12-01",{"date":291,"type":21},"2028-12-31",{"name":293,"class":57},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100603142","mri-guided-brachytherapy-and-salvage-sbrt-program-100603142","NCT07132671","MRI-guided Brachytherapy and Salvage SBRT Program","MRI-guided Brachytherapy + Salvage SBRT Program for Patients With Prostate Bed Relapses After Radical Prostatectomy","Patients with increasing PSA after RP and clinical evidence of PET PSMA\u002FCholine+ and RMN+ isolated prostatic bed relapse (IPBR) that is implantable via transperineal route . The IPBR should be visible on TRUS imaging to allow proper implant placement.\n\n1. Pathological confirmation is advised in all cases but it is not mandatory .\n2. Patients with any of the following were not considered eligible:\n\n   1. Distance \\\u003C 5mm from the edge of the IPBR to any of the defined OARs (UV anastomosis, rectal wall, bladder wall, external urinary sphincter)\n   2. Distant Metastases\n   3. Isolated nodal relapses\n   4. Prior Irradiation to the IPBR area\n   5. Multicentric IPBRs\n   6. Life expectancy of less than 5 years or inability to tolerate and comply with an HDR procedure\n3. No prior radiation therapy to the target areas;\n4. Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including maximal TURBT and concomitant chemotherapy;\n5. WBC equal or greater than 3500 mm3; platelet count equal or greater than 135000 mm3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n6. Ability to undergo MRI scanning.",{"count":302,"type":21},29,[24],"Brachytherapy followed by MRI-guided irradiation has the potential to improve treatment results in patients with local relapses after radical prostatectomy",[28],[29,307,308,309],"Prostate Bed Relapse","Brachytherapy","MR-Guided SBRT","2025-08-12",{"date":312,"type":50},"2025-08-20",{"date":314,"type":21},"2025-10-01",{"date":316,"type":21},"2030-06-30",{"name":318,"class":57},"Clinica Universidad de Navarra, Universidad de Navarra",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":122},"100600764","effects-of-hypopressive-exercises-on-urinary-incontinence-and-erectile-dysfunction-after-radical-prostatectomy-100600764","NCT07101731","Effects of Hypopressive Exercises on Urinary Incontinence and Erectile Dysfunction After Radical Prostatectomy","The Effects of Hypopressive Exercises on Urinary Incontinence and Erectile Dysfunction After Radical Prostatectomy: A Randomized Controlled Trial","Inclusion Criteria\n\n* Male individuals diagnosed with prostate cancer who have undergone radical prostatectomy\n* Experiencing both urinary incontinence and erectile dysfunction\n* Age \\> 55 years\n* A score of 24 or higher on the Mini-Mental State Examination (MMSE)\n* Literate (able to read and write)\n* Willingness to participate in the study (signed informed consent)\n* Ability to voluntarily contract pelvic floor muscles\n* Ability to cooperate with the assessments and interventions used in the study\n\nExclusion Criteria\n\n* History of urinary incontinence before surgery\n* Congenital abnormalities of the urinary system\n* Presence of neurological disorders\n* History of transurethral resection of the prostate (TURP)\n* Diagnosis of chronic obstructive pulmonary disease (COPD) and\u002For chronic restrictive pulmonary disease\n* History of inguinal hernia\n* Previous or current history of radiation therapy\n* Surgical or postoperative complications that prevent early physiotherapy intervention (e.g., urinary tract infection, bladder neck stenosis)","55 Years",{"count":328,"type":21},30,[24],"This randomized controlled trial investigates the effects of hypopressive exercises on urinary incontinence and erectile dysfunction in men following radical prostatectomy. Participants will be randomly assigned to one of two groups: a control group receiving home-based pelvic floor muscle exercises and an experimental group receiving both pelvic floor muscle exercises and supervised hypopressive exercises twice per week. The study aims to determine whether the addition of hypopressive techniques, which target coordinated activation of the pelvic floor and abdominal muscles without increasing intra-abdominal pressure, offers greater improvements in urinary and sexual function. Primary outcomes include pelvic floor muscle strength and endurance, while secondary outcomes include urinary incontinence severity, erectile function, and quality of life.",[28,208,201,207],[203,208,333,207,334],"Erectile Dysfunction","Hypopressive Exercises","2025-07-28",{"date":337,"type":50},"2025-08-03",{"date":339,"type":50},"2024-06-01",{"date":341,"type":21},"2025-11-15",{"name":343,"class":57},"Bartın Unıversity",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":354,"conditions":355,"keywords":356,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":122},"100585843","phase-2-comparative-performance-of-64copper-64cu-sar-bis-psma-vs-68ga-psma-11-pet-ct-for-the-detection-of-prostate-cancer-recurrence-in-the-setting-of-biochemical-failure-following-radical-prostatectomy-100585843","NCT06907641","Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy","Co-PSMA","Inclusion Criteria:\n\n* Male patients aged 18 or above\n* Ability to provide informed consent documentation indicating that they understand the purpose of, and procedures required for the study, and are willing to participate in the study.\n* Prior radical prostatectomy for confirmed adenocarcinoma on histopathology.\n* Rising PSA (0.20 - 0.75 ng\u002FmL) following radical prostatectomy with no prior salvage radiotherapy.\n* 68Ga PSMA-11 PET\u002FCT within the last 4 weeks for prostate cancer biochemical recurrence.\n\nExclusion Criteria:\n\n* Prior, or contraindication to, salvage radiotherapy for biochemically recurrent prostate cancer.\n* History of current active malignancy as per investigator discretion other than prostate cancer.\n* Known or expected hypersensitivity to 64Cu-SAR-bisPSMA\n* Systemic therapy for metastatic prostate cancer including androgen deprivation therapy.",{"count":252,"type":21},[353],"PHASE2","The goal of this clinical trial is to compare 64Cu-SAR-bisPSMA PET\u002FCT and 68Ga PSMA-11 PET\u002FCT in men with biochemical failure following radical prostatectomy. The main questions it aims to answer are:\n\n* Is there a difference in the number of lesions of prostate cancer recurrence detected between the 64Cu-SAR-bisPSMA PET\u002FCT and 68Ga PSMA-11 PET\u002FCT scans.\n* What is the diagnostic accuracy of 64Cu-SAR-bisPSMA PET\u002FCT compared to 68Ga PSMA-11 PET\u002FCT using a standard of care comparator.\n* Evaluate the magnitude of clinical management change when using 64Cu-SAR-bisPSMA additional to standard of care imaging (68Ga PSMA-11).\n\nParticipants will:\n\n* have 3 visits: 1) standard of care 68Ga PSMA-11 dose and PET\u002FCT scan; 2) 64Cu-SAR-bisPSMA dose and PET\u002FCT; 3) 64Cu-SAR-bisPSMA PET\u002FCT only\n* have standard of care blood test either at Visit 1 or Visit 2",[28],[29,357,358,349,359,360,361,203,362,363],"Salvage Radiotherapy","Prostatectomy","CLP11","Prostate Cancer Recurrence","Biochemical Failure","Copper","PET scan","2025-04-01",{"date":366,"type":50},"2025-04-02",{"date":368,"type":50},"2024-11-21",{"date":370,"type":21},"2025-11",{"name":372,"class":57},"St Vincent's Hospital, Sydney",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":396},"100572961","the-application-of-somatosensory-interactive-pelvic-floor-muscle-training-for-stress-urinary-incontinence-in-men-underwent-radical-prostatectomy-100572961","NCT06740071","The Application of Somatosensory Interactive Pelvic Floor Muscle Training for Stress Urinary Incontinence in Men Underwent Radical Prostatectomy","Inclusion Criteria:\n\n* PCa patients aged 18 to 85 years who had undergone laparoscopic radical prostatectomy (RP)\n\nExclusion Criteria:\n\n* patients currently participating in other clinical trials and those unable to cooperate with study interventions and follow-up procedures due to specific factors","85 Years",{"count":381,"type":21},100,[24],"The study aims to compare the efficacy of different pelvic floor muscle training (PFMT) modes on improving urinary incontinence (UI) recovery in prostate cancer (PCa) patients after radical prostatectomy (RP). The methods being compared include standard PFMT (S-PFMT) , a somatosensory interactive PFMT (SI-PFMT, an enhanced PFMT) , and a standard PFMT combined with pelvic floor muscle magnetic stimulation (S-PFMT+MS). Eligible participants are randomized into either of the groups to receive different modalities of post-operative PFMT.\n\nSubjects in the S-PFMT group received traditional verbal instructions and paper-based educational materials. For the SI-PFMT group, an interactive experiential education model was adopted. First, an educational video introduced the importance and basic information of postoperative PFMT. Then, synchronized PFMT guidance through a combination of audio and video would be used. Subjects assigned to the S-PFMT+MS group, on the basis of traditional verbal and paper-based education, pelvic floor magnetic stimulation therapy was applied using a pelvic floor magnetic stimulator, operated by the same experienced rehabilitation physician.\n\nSelf administered questionnaires and 1-hour pad test would be used to assess the treatment outcomes at 1, 3, and 6 months postoperatively.",[28],[386,387],"pelvic floor muscle training","post operative urinary incontinence",{"date":389,"type":50},"2025-04-04",{"date":391,"type":50},"2023-05-01",{"date":393,"type":21},"2027-04",{"name":395,"class":57},"The University of Hong Kong",2,{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":425,"leadSponsor":427,"locationsCount":122},"100586479","robotic-prostatectomy-artificial-intelligence-low-pressure-pain-ralp-trial-100586479","NCT06915909","Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial","Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial - \"The Monitoring of Patients Outcomes Intraoperatively and Perioperatively Using the Airseal and Stryker Insufflator Undergoing Robotic Assisted Laparoscopic Prostatectomy at a Pressure and Stability of Pneumoperitoneum of 8 mmHg\"","Inclusion Criteria:\n\n* Patient indicated for non-emergent robotic Prostatectomy surgery\n* Patients (or appropriate legal representatives) able to provide written informed consent to participate in the study\n* Males, aged 18 to 75 years\n* Have no significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and\u002For behavioural recommendations and office visits\n* Are American Society of Anaesthesiologists (ASA) Class I, II, or III);\n\nExclusion Criteria:\n\n* Patient participation in a different investigational clinical study within 90 days before screening and for the duration of this trial (unless previously approved by the investigator and Sponsor);\n* Patients requiring any surgical procedure in addition to Prostatectomy and or \u002F Pelvic Lymph node dissection\n* Previous pelvic surgery or previous malabsobtion or restrictive procedures performed for the treatment of obesity\n* Inability to provide informed consent\n* Unable or unwilling to attend follow-up visits and examinations\n* Uncontrolled hypertension (=\u002F\\>Systolic: 180 mmHg\u002FDiastolic: 120 mmHg) and\u002For diabetes mellitus (Blood sugar level: \\>200 mg\u002FdL)\n* Patients who fall into American Society of Anesthesiologists (ASA) Class ≥ IV\n* History of chronic alcohol or drug abuse within 2 years of the screening visit\n* Chronic renal failure or on dialysis\n* Significant complicating medical history or immunocompromised\n* History or presence of pre-existing autoimmune connective tissue disease, e.g., systemic lupus erythematosus or scleroderma\n* Immunocompromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders;\n* Any medical condition which precludes compliance with the study\n* Subjects with any other clinically significant unstable medical disorder, life threatening disease, or conditions that, in the opinion of the investigator, may jeopardize the subject's well-being and\u002For the soundness of this clinical study or which would contra-indicate a surgical procedure.\n* Previous or current history of being on regular analgesia \u002F pain killers","75 Years",{"count":406,"type":21},40,[24],"The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the removal of prostate cancers. The data collected will inform methodologies for future, larger, multi-center trials investigating pain in patients undergoing prostate cancer surgery.\n\nA robotic prostatectomy is a commonly performed surgery used to treat prostate cancer by removing the prostate gland. In order to perform the procedure, the surgeon must 'inflate' (technical term pneumoperitoneum) the patients abdomen with carbon dioxide gas using a device called an insufflator. Adequate 'inflation' of the abdomen ensures the surgeon can clearly visualise the prostate. Unfortunately, higher pressures of abdominal 'inflation' are a large contributor to intra and post-operative pain in patients having prostatectomies. The type of insufflator device used to maintain inflation pressures in the abdomen are thought to be a variable contributing to differing levels of intra and post-operative pain. Therefore, the purpose of this trial is to compare intra and post-operative pain when using two different insufflator devices when performing robotic prostatectomies. Both insufflators are already commonly used across multiple NHS Trusts.\n\n40 patients awaiting a robotic prostatectomy at the urology department at the Lister hospital, Stevenage, will be randomised to use either the Conventional Insufflator System (CIS) {Stryker PneumoClear Insufflator} or the AIRSEAL® Insufflation System (AIS) to 'inflate' their abdomens during their prostatectomies. Data relating to various intra and post-operative outcomes will be collected in the 30 days following the patient's operation. Outcomes include levels of intra and post-operative pain, medication use, procedure time, recovery room time, length of hospital stay, post operative nausea and vomiting and adverse events. This data can be analysed to identify trends in differences in outcomes between the AIS and CIS insufflators.",[162,28,410,411,412,358],"Prostate Cancer Surgery","Prostate Cancers","Prostate Neoplasm",[77,83,414,415,416,417,418,419,420],"robotic prostatectomy","post-operative pain","pain","Stryker PneumoClear insufflator","AirSeal Insufflation System","intra-operative pain","Medasense","2025-03-31",{"date":423,"type":50},"2025-04-08",{"date":364,"type":21},{"date":426,"type":21},"2025-07-01",{"name":428,"class":429},"East and North Hertfordshire NHS Trust","OTHER_GOV",{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":439,"conditions":440,"keywords":441,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":122},"100563539","phase-2-pet-scan-study-to-detect-prostate-cancer-in-patients-with-early-psa-recurrence-100563539","NCT06617481","PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence","Inclusion Criteria:\n\n* History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.\n* An elevated PSA test result that is greater than or equal to 0.1 ng\u002Fml and less than 0.5\n\nExclusion Criteria:\n\n* Patients who are planned to have an x-ray contrast agent or other PET radiotracer \\& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.\n* Patients currently receiving Androgen Deprivation Therapy (ADT).",{"count":328,"type":21},[353],"Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.\n\nThe research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.",[28],[442],"Rising PSA following cancer prostatectomy surgery","2024-10-22",{"date":445,"type":50},"2024-10-24",{"date":447,"type":50},"2024-09-20",{"date":449,"type":21},"2027-10-10",{"name":451,"class":57},"AdventHealth",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":460,"briefSummary":461,"conditions":462,"keywords":466,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":479},"100565015","phase-2-fk-pc101-as-adjuvant-therapy-for-men-with-high-risk-prostate-cancer-100565015","NCT06636682","FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy","Inclusion Criteria:\n\n* Has localized high-risk or very high-risk prostate cancer based on the NCCN v4.2023 classification.\n* Has ≥3 prostate biopsy cores with ≥50% tumor involvement.\n* Has PSA \\>4 ng\u002FmL ≤28 days prior to enrollment.\n* Has no evidence of distant metastases based on PSMA-PET\u002FCT performed ≤28 days prior to enrollment.\n* Is a candidate for radical prostatectomy, and scheduled radical prostatectomy date must be 3 to 14 days after enrollment.\n* Has not received nor plans to receive neoadjuvant (preoperative) radiation therapy, androgen deprivation therapy (ADT), or any other anticancer therapy.\n* Has a life expectancy \\>5 years.\n\nAdditional key eligibility criteria immediately postoperative for inclusion in the randomized population include:\n\n* Stage \\>pT3a (tumor has extended outside of the prostate on one side).\n* Gleason score of 8, 9, or 10 (high\u002Fvery high) on prostatectomy specimen.\n* Subjects with pT3b or pT4 tumors with a Gleason sum 7 (4+3) are eligible.\n* Pelvic lymph node dissection (PLND) is required with either pN0 or pN1 nodal staging permitted.\n* Subjects must have negative surgical margins or microscopic-only positive surgical margins.\n\nFinal eligibility criteria at 2 months postoperative for randomization include:\n\n* FK-PC101 has been produced for the subject and meets all release specifications.\n* An undetectable PSA (\\\u003C0.04 ng\u002FmL) on the most recent test performed prior to randomization (Day -4 to -7).\n* No prior, current, or planned future postoperative or adjuvant XRT, hormonal therapy such as ADT, or any other anticancer therapy (future therapy should not be administered until evidence exists of prostate cancer disease recurrence \\[such as PSA recurrence\\]).\n* Adequate organ function based on CBC and chemistry studies within 2 weeks of Day 1 (Day -14 to -7). Specific laboratory requirements include:\n\n  * Absolute neutrophil count (ANC) \\>1000\u002FµL\n  * Platelet count \\>100,000\u002FµL.\n  * Hemoglobin \\>8.0 gm\u002FdL.\n  * Estimated glomerular filtration rate (eGFR) \\>60 mL\u002Fminute based on Cockcroft-Gault formula.\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both \\\u003C2 × upper limit of normal (ULN).\n  * Albumin \\>3.0 gm\u002FdL.\n* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions of the study.\n\nExclusion Criteria:\n\n* Has an additional active malignancy that may confound the assessment of the study endpoints. If the subject has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the Sponsor before study entry. Note: Subjects with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including breast DCIS, transitional cell carcinoma\u002FNMIBC, anal carcinoma, and melanoma in situ).\n* Is eligible for and elects to receive adjuvant therapy following RP.\n* Has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association \\[NYHA\\] Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina, pulmonary embolism or stroke within 6 months prior to study entry, uncontrolled hypertension, or clinically significant arrhythmias not controlled by medication).\n* Has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the subject at significant risk for pulmonary complications during the study.\n* Has known metastases, such as bone, visceral, or brain or leptomeningeal metastases.\n* Has an active autoimmune disease or Grade ≥3 pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbamazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.\n* Is currently receiving systemic steroid therapy at a prednisone equivalent dose of \\>10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to enrollment.\n* Has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Is at risk for disseminated BCG infection or has previously demonstrated an allergic response to BCG or its components.\n* Has known positive status for human immunodeficiency virus (HIV) or active or chronic Hepatitis (Hep) B or Hep C. Screening is not required.\n* Has any medical condition which in the opinion of the Investigator places the subject at an unacceptably high risk for toxicity.",{"count":381,"type":21},[353],"The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are:\n\nDoes FK-PC101 delay or prevent the return of prostate cancer following surgery? What medical problems do participants (subjects) have when taking FK-PC101?\n\nResearchers will compare FK-PC101 to current treatment practice to see if FK-PC101 works to prevent or delay the return of prostate cancer following surgery to remove the prostate cancer tumor.\n\nSubjects will:\n\nHave a sample of the prostate cancer tissue collected at the time of surgery to remove this tissue from the body. This tissue will then be used to create a personalized vaccine that is specific to your prostate cancer.\n\nIf randomly selected to receive the vaccine, subjects will receive the vaccine up to 7 times over a 6-month period.\n\nIn addition to the treatment visits for those randomized to receive FK-PC101, there will be up to 4 follow up visits to the clinic over a 22-month (nearly 2 year) period.\n\nFor subjects randomized to receive current treatment practice, they will be asked to attend up to 8 visits over 22 months to track if there is any detectable cancer. Should their prostate cancer return within a year following surgery, they will be eligible to receive FK-PC101, which already had been produced and thus no additional tumor tissue would need to be obtained.\n\nSubjects in both study arms will have regular blood tests and scans to test whether their prostate cancer has returned.",[162,463,411,28,29,464,465],"Prostate CA","Prostate Cancer Patients Undergoing Radical Prostatectomy","High-risk Prostate Cancer",[467,358,468,203],"Vaccine","Autologous","2024-10-17",{"date":471,"type":50},"2024-10-21",{"date":473,"type":50},"2024-10-14",{"date":475,"type":21},"2027-05-04",{"name":477,"class":478},"Cellvax Therapeutics Inc","INDUSTRY",3]